See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Fitusiran Approved for Hemophilia A and B

Summary by MedPage Today
(MedPage Today) -- The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages 12 years and up with hemophilia A or B, with or without factor VIII or IX inhibitors. "Today's approval of...

10 Articles

All
Left
Center
2
Right
MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Fitusiran Approved for Hemophilia A and B

(MedPage Today) -- The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages 12 years and up with hemophilia A or B, with or without factor VIII or IX inhibitors. "Today's approval of...

·New York, United States
Read Full Article
biopharmadive.combiopharmadive.com
Center

FDA approves first-of-its-kind RNA drug for hemophilia

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.

Read Full Article
csimarket.comcsimarket.com

# RNAi Revolution Alnylam?s Qfitlia Approval Marks a New Horizon for Hemophilia and Beyond,

In a groundbreaking development that promises to redefine treatment standards, Alnylam Pharmaceuticals, Inc. has recently achieved a significant milestone in the realm of RNA interference (RNAi) therapeutics. The U.S. Food and Drug Administration (FDA) has granted approval for Qfitlia (fitusiran), marking it as the first siRNA therapeutic approved for the treatment of Hemophilia A and B. This approval not only represents a major step forward for…

Read Full Article
drugtopics.comdrugtopics.com

FDA Approves Fitusiran as Prophylaxis of Bleeding Episodes Due to Hemophilia A or B

Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.

Read Full Article
Pharmacy TimesPharmacy Times

FDA Approves Fitusiran For Prophylactic Hemophilia A, B Treatment Regardless of Inhibitor Status

Approval of fitusiran, a small interfering RNA drug, was found effective in patients with hemophilia regardless of inhibitor status.

Read Full Article
ajmc.comajmc.com

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety and efficacy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hcplive.com broke the news in on Thursday, March 27, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal